SCHEMBL3577343

SCHEMBL3577343

CCOC(=O)c1cc(Cl)cc(F)c1N(C(C)=O)C(C)=O

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GAA P10253 3/20 0.40
NPC1 O15118 1/20 0.40
POLB P06746 1/20 0.40
ALDH1A1 P00352 4/20 0.39
KDM4E B2RXH2 3/20 0.39
HPGD P15428 3/20 0.39
MAPK1 P28482 2/20 0.39
GLA P06280 1/20 0.39
MAPT P10636 2/20 0.39
L3MBTL1 Q9Y468 2/20 0.39
LMNA P02545 1/20 0.39
TSHR P16473 2/20 0.39
MAOB P27338 1/20 0.39
CYP4F2 P78329 1/20 0.39
CYP4A11 Q02928 1/20 0.39
BAZ2B Q9UIF8 1/20 0.39
BAZ2A Q9UIF9 1/20 0.39
KMT2A Q03164 3/20 0.38
JMJD6 Q6NYC1 1/20 0.38
EGFR P00533 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3585477 0.77 ALDH1A1 (0.52) GAAPOLBALDH1A1KDM4EHPGD
SCHEMBL3573157 0.74 CA12 (0.42) KDM4EHPGDMAPK1MAPTTSHR
SCHEMBL19971601 0.74 MAPK1 (0.52) KDM4EHPGDMAPK1MAPTTSHR
SCHEMBL7992264 0.73 MAPK1 (0.51) NPC1KDM4EMAPK1TSHRMAOB
SCHEMBL28727227 0.72 CA1 (0.49) ALDH1A1KDM4EMAPK1TSHRMAOB
SCHEMBL16529335 0.70 SYK (0.42) GAAPOLBALDH1A1KDM4EHPGD
SCHEMBL17321013 0.69 MAOB (0.44) GAAALDH1A1KDM4EHPGDMAPK1
SCHEMBL2549970 0.69 LMNA (0.60) GAAPOLBHPGDMAPTL3MBTL1
SCHEMBL30998146 0.69 CYP4F2 (0.50) ALDH1A1HPGDMAPTL3MBTL1LMNA
SCHEMBL31255110 0.69 MAPT (0.47) GAANPC1POLBALDH1A1KDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1984340-B1 ANTHRANILAMIDE/2-AMINO-HETEROARENE CARBOXAMIDE DERIVATIVES HOFFMANN LA ROCHE (CH) 2012-06-27 EP disclosed
US-7678818-B2 Anthranilamide and 2-amino-heteroarene-carboxamide compounds HOFFMANN-LA ROCHE INC. (US) 2010-03-16 US disclosed
EP-1984340-A1 ANTHRANILAMIDE/2-AMINO-HETEROARENE CARBOXAMIDE DERIVATIVES F.HOFFMANN-LA ROCHE AG (CH) 2008-10-29 EP disclosed
US-20070219261-A1 Anthranilamide and 2-amino-heteroarene-carboxamide compounds HOFFMANN-LA ROCHE INC. 2007-09-20 US disclosed
WO-2007090752-A1 ANTHRANILAMIDE/2-AMINO-HETEROARENE CARBOXAMIDE DERIVATIVES F. HOFFMANN-LA ROCHE AG (CH) 2007-08-16 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070219261-A1 Anthranilamide and 2-amino-heteroarene-carboxamide compounds AADAT, AAAS, AADAC GAA 450/4885NPC1 3237/4885POLB 1741/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.